Orexin-A vs Efinopegdutide
Head-to-head comparison of Orexin-A (Hypocretin-1 (Orexin-A)) and Efinopegdutide (Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Orexin-A | Efinopegdutide |
|---|---|---|
| Category | Cognitive Enhancement | Weight Management |
| Full Name | Hypocretin-1 (Orexin-A) | Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | 3562 Da | N/A |
| Half-Life | Minutes to <1 hour | Approximately 1 week |
| Amino Acids | 33 | N/A |
| Typical Dose | Research-only; no validated human dose | Trial-dependent; weekly SC dosing |
| Route | Intracerebroventricular/Intranasal | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 42 | 14 |
| Research Status | Pre-clinical | Clinical |
Orexin-A Benefits
- ✓wakefulness
- ✓attention
- ✓memory consolidation
- ✓fatigue resistance
Efinopegdutide Benefits
- ✓reduced body weight
- ✓improved insulin sensitivity
- ✓reduced liver fat
- ✓greater satiety
Orexin-A Dosing
Research-only i.c.v. microgram/nanomolar studies|intranasal experimental use|no established human protocol
Efinopegdutide Dosing
once-weekly subcutaneous injection|dose escalation during lead-in|maintenance dosing in trials
Orexin-A Side Effects
- ⚠insomnia
- ⚠headache
- ⚠blood pressure changes
Efinopegdutide Side Effects
- ⚠nausea
- ⚠decreased appetite
- ⚠fatigue
Research Overview
Orexin-A
Preclinical studies link orexin signaling to arousal, learning, and memory consolidation, making orexin-A a candidate for cognition-related research. It is not an approved cognitive enhancer and remains an experimental peptide.
Efinopegdutide
Human trials have shown meaningful weight loss and improvements in hepatic steatosis biomarkers. It remains a research compound with ongoing development in metabolic disease.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.